Aria Shokoohi

Publication Activity (10 Years)

Years Active: 2019-2023
Publications (10 Years): 9

Top Topics

Positron Emission Tomography

Ejection Fraction

Advanced Non Small Cell Lung Cancer

Top Venues

Current oncology (Toronto, Ont.)

JCO oncology practice

Cancer medicine

This page only lists publications with an associated author ORCID identifier.

Publications

Rebekah Rittberg, Bonnie Leung, Aria Shokoohi, Alexandra Pender, Selina K Wong, Zamzam Al-Hashami, Ying Wang, Cheryl Ho
Real-World Outcomes of Stage IV NSCLC with PD-L1 ≥ 50% Treated with First-Line Pembrolizumab: Uptake of Second-Line Systemic Therapy. Current oncology (Toronto, Ont.) 30 (6) (2023)
Rebekah Rittberg, Bonnie Leung, Aria Shokoohi, Alexandra Pender, Selina K Wong, Zamzam Al-Hashami, Ying Wang, Cheryl Ho
Real-World Outcomes of Stage IV NSCLC with PD-L1 ≥ 50% Treated with First-Line Pembrolizumab: Uptake of Second-Line Systemic Therapy. Current oncology (Toronto, Ont.) 30 (6) (2023)
Rebekah Rittberg, Bonnie Leung, Aria Shokoohi, Alexandra Pender, Selina K Wong, Zamzam Al-Hashami, Ying Wang, Cheryl Ho
Real-World Outcomes of Stage IV NSCLC with PD-L1 ≥ 50% Treated with First-Line Pembrolizumab: Uptake of Second-Line Systemic Therapy. Current oncology (Toronto, Ont.) 30 (6) (2023)
Marie-Hélène Denault, Jamie Feng, Shelley Kuang, Aria Shokoohi, Bonnie Leung, Mitchell Liu, Eric Berthelet, Janessa Laskin, Sophie Sun, Tina Zhang, Cheryl Ho, Barbara L Melosky
Beyond PACIFIC: Real-World Outcomes of Adjuvant Durvalumab According to Treatment Received and PD-L1 Expression. Current oncology (Toronto, Ont.) 30 (8) (2023)
Rebekah Rittberg, Bonnie Leung, Aria Shokoohi, Alexandra Pender, Selina K Wong, Zamzam Al-Hashami, Ying Wang, Cheryl Ho
Real-World Outcomes of Stage IV NSCLC with PD-L1 ≥ 50% Treated with First-Line Pembrolizumab: Uptake of Second-Line Systemic Therapy. Current oncology (Toronto, Ont.) 30 (6) (2023)
Lauren Jones, Rebekah Rittberg, Bonnie Leung, Aria Shokoohi, Alexandra Pender, Selina K Wong, Zamzam Al-Hashami, Ying Wang, Cheryl Ho
Alternate Pembrolizumab Dosing Interval in Advanced NSCLC with PD-L1 TPS ≥ 50%: 3 Weekly Compared to 6 Weekly Dosing. Current oncology (Toronto, Ont.) 29 (11) (2022)
Cheryl Ho, Brandon Chan, David Cameron, Aria Shokoohi, Deirdre Weymann, Howard J Lim
Readiness of Healthcare Systems to Generate Real-World Evidence: Reliability of CT Radiographic End Points for Evaluation of First-Line Systemic Treatment. JCO oncology practice 17 (12) (2021)
Aria Shokoohi, Zamzam Al-Hashami, Sara Moore, Alexandra Pender, Selina K Wong, Ying Wang, Bonnie Leung, Jonn Wu, Cheryl Ho
Effect of targeted therapy and immunotherapy on advanced nonsmall-cell lung cancer outcomes in the real world. Cancer medicine (2021)
Amirrtha Srikanthan, Bonnie Leung, Aria Shokoohi, Alannah M Smrke, Alan Bates, Cheryl Ho
Psychosocial Distress Scores and Needs among Newly Diagnosed Sarcoma Patients: A Provincial Experience. Sarcoma 2019 (2019)